Clinical trial
Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After…
NCT00485979 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00485979 |
|---|---|
| Title | Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients |
| Official title | A Randomized, Open-label, Multi-center Study of Larotaxel at 90mg/m2 or Docetaxel Every 3 Weeks, Alone or in Combination With Trastuzumab According to Her2neu Status, Administered After a Combination of Anthracycline and Cyclophosphamide as Pre-operative Therapy in Patients With High Risk Localized… |
| Acronym | SATIN |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | larotaxel (XRP9881), docetaxel, trastuzumab |
| Enrollment | 330 |
| Start date | Jun 1, 2007 |
| Primary completion | Aug 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Jun 13, 2007 |
| Last update posted | Jun 28, 2011 |
| Countries | Belgium, Brazil, France, Germany, Poland, Tunisia, United Kingdom, Uruguay |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: